DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 14, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

June 25, 2026

Conditions
Small Cell Lung Carcinoma (SCLC)
Interventions
DRUG

BI 764532

BI 764532

DRUG

Carboplatin

Carboplatin

DRUG

Etoposide

Etoposide

DRUG

Atezolizumab

Atezolizumab

DRUG

Durvalumab

Durvalumab

DRUG

Cisplatin

Cisplatin

Trial Locations (22)

1011

University Hospital of Lausanne, Lausanne

1200

Cliniques Universitaires Saint-Luc, Brussels

8500

Kortrijk - HOSP AZ Groeninge Kennedylaan, Kortrijk

28034

Hospital Universitario Ramon Y Cajal, Madrid

28040

Fundación Jiménez Díaz, Madrid

30322

Emory University, Atlanta

32806

Orlando Health Cancer Institute, Orlando

33000

INS Bergonie, Bordeaux

35392

Universitätsklinikum Gießen und Marburg GmbH, Giessen

41009

Hospital Virgen Macarena, Seville

46009

Instituto Valenciano de Oncología, Valencia

46010

Hospital Clínico de Valencia, Valencia

67091

HOP Civil, Strasbourg

69677

HOP Louis Pradel, Bron

94805

INS Gustave Roussy, Villejuif

350-1298

Saitama Medical University International Medical Center, Saitama, Hidaka

431-3192

Hamamatsu University Hospital, Shizuoka, Hamamatsu

104-0045

National Cancer Center Hospital, Tokyo, Chuo-ku

135-8550

Japanese Foundation for Cancer Research, Tokyo, Koto-ku

80-214

Medical University Gdansk, Gdansk

93-338

Polish Mother's Memorial Hospital - Research Institute, Lodz

60-693

MED POLONIA SP Z O O, Clinical Trials Department,Poznan, Poznan

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06077500 - DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter